Please wait a minute...
European Journal of Gynaecological Oncology  2021, Vol. 42 Issue (1): 38-44    DOI: 10.31083/j.ejgo.2021.01.2119
Original Research Previous articles | Next articles
The European Vulvovaginal Epidemiological Survey (EVES) in Italy. Impact of vulvovaginal atrophy on the quality of life and sexual function in breast cancer survivors
Rossella E. Nappi1, *(), Nicoletta Biglia2, Ettore Cicinelli3, Tiziana Di Paolantonio4, Stefano Luisi5, Massimo Stomati6, Paola Villa7, 8, on behalf of the EVES study investigators§
1Research Centre for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS Policlinico San Matteo Foundation, University of Pavia, 27100 Pavia, Italy
2University of Turin, Department of Surgical Sciences, Mauriziano Umberto I Hospital, 10128 Turin, Italy
32nd Unit of Obstetrics and Gynecology, Department of Biomedical and Human Oncological Science (DIMO), University of Bari, 70121 Bari, Italy
4Shionogi srl, 00193 Rome, Italy
5Department of Molecular and Developmental Medicine, Division of Obstetrics and Gynecology, University of Siena, 53100 Siena, Italy
6Division of Obstetrics and Gynecology, Department of Gynecology and Obstetrics, "D. Camberlingo" Hospital, Francavilla Fontana, ASL Brindisi, 72100 Brindisi, Italy
7Department of Women, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy
8Catholic University of Sacred Heart, Rome, 00168 Rome, Italy
Download:  PDF(197KB)  ( 69 ) Full text   ( 23 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
The European Vulvovaginal Epidemiology Survey (EVES) sub-analysis assesses the impact of history of breast cancer (HBC) on vulvovaginal atrophy (VVA), sexual function and quality of life in a sample of postmenopausal women. Women aged 45-75 years with at least one symptom of VVA attending Italian menopause centers were included; subgroup data were described according to the absence (N = 967) or presence (N = 78) of HBC. VVA confirmed by gynecological examination and Vaginal Health Index < 15 was more prevalent in women with HBC (93.6% vs. 86.0% and 78.2% vs. 65.9%, respectively). Self-reported vaginal discharge, itching and urinary frequency were more prevalent in women without HBC compared to different HBC subgroups. Day-to-Day Impact of Vaginal Aging (DIVA) and sexual function scores were similar between women with or without HBC, but women who have completed breast cancer (BC) therapy showed lower sexual distress. Women with HBC had a higher vaginal prevalence and severity of signs of VVA, while self-reported VVA symptoms were generally less disruptive in women with HBC. These exploratory findings warrant confirmation in larger studies.
Key words:  Breast cancer      Menopause      Gynecological examination      Quality of life      Sexual dysfunction      Vulvovaginal atrophy      Genitourinary syndrome of menopause     
Submitted:  30 April 2020      Revised:  31 August 2020      Accepted:  27 October 2020      Published:  15 February 2021     
*Corresponding Author(s):  Rossella E. Nappi     E-mail:  renappi@tin.it
About author: 
§The complete list of the EVES Study investigators participating from Italian sites is as follows:
A. M. Becorpi (Florence, Italy), P. Benedetti Panici (Rome, Italy), C. Benedetto (Turin, Italy), N. Biglia (Turin, Italy), M. Busacca (Milan, Italy), A. Cagnacci (Modena, Italy), A. Cianci (Catania, Italy), E. Cicinelli (Bari, Italy), F. De Seta (Trieste, Italy), C. Di Carlo (Naples, Italy), M. Gambacciani (Pisa, Italy), M. Guida (Salerno, Italy), S. Luisi (Siena, Italy), D. Marchesoni (Udine, Italy), R.E. Nappi (Pavia, Italy), A. M. Paoletti (Cagliari, Italy), S. Palacios (Madrid, Spain), A. Pellegrino (Lecco, Italy), V. Remorgida (Genoa, Italy), S. Salvatore (Milan, Italy), R. Seracchioli (Bologna, Italy), M. Stomati (Brindisi, Italy), N. Surico (Novara, Italy), P. Villa (Rome, Italy).

Cite this article: 

Rossella E. Nappi, Nicoletta Biglia, Ettore Cicinelli, Tiziana Di Paolantonio, Stefano Luisi, Massimo Stomati, Paola Villa, on behalf of the EVES study investigators. The European Vulvovaginal Epidemiological Survey (EVES) in Italy. Impact of vulvovaginal atrophy on the quality of life and sexual function in breast cancer survivors. European Journal of Gynaecological Oncology, 2021, 42(1): 38-44.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2021.01.2119     OR     https://ejgo.imrpress.com/EN/Y2021/V42/I1/38

[1] Aldo Iop, Pamela Driol, Alessandra Zacchia, Manuela Miscoria. Cytoplasmic pollen extract for treatment of menopausal symptoms in breast cancer patients: a case series report[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 45-49.
[2] Yu-Yi Ou, Shuang Liu, Jian-Lan Zhang, Hui-Zhi Yuan, Yu-Hua Zheng. Effects of whole-course standardized nursing and humanistic care on the sleep condition and quality of life of elderly patients undergoing hysterectomy for cervical cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 154-160.
[3] Qing-Hui Kan, Ying-Lin Wang, Mei-Ling Xu, Fu-Yun Tong, Yong-Sheng Shi. Network meta-analysis of targeted drugs in combination with chemotherapy for advanced/metastatic triple-negative breast cancer treatment[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 897-905.
[4] Polyana Barbosa Silva, Millena Prata Jammal, Márcia Antoniazi Michelin, Eddie Fernando Cândido Murta. Phenotypic differences of tecidual TDCs obtained from breast cancer mice[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 689-698.
[5] Huifen Zhen, Fan Guo, Xiaojun Zhang, Miaomiao Jia, Haibo Yang, Yarong Yao, Yuandong Li, Jinnan Gao. The effects of chemotherapy with anthracyclines vs capecitabine on tumour size, survival rate and estradiol levels in patients with locally advanced breast cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 785-789.
[6] Katselashvili Lika, Jokhadze Natia, Katcharava Margarita, Vardiashvili Nino. Breast Cancer Metastatic to Vulva - a Case Report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 845-848.
[7] T. Uehara, A. Mitsuhashi, M. Shozu. The impact of pre-existing polycystic ovary syndrome on endometrial cancer recurrence[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 668-674.
[8] Hayal Uzelli Şimşek, Turgay Şimşek, Deniz Şahin, Sertaç Ata Güler, Nuh Zafer Cantürk, Nihat Zafer Utkan. Evaluation of the effect of surgical timing on systemic response to trauma in premenopausal patients by using cytokine levels[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 577-582.
[9] Isao Otsuka. Clear cell carcinoma of the vagina followed by breast cancer in a patient without prenatal diethylstilbestrol exposure[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 638-639.
[10] Luca Roncati, Maria Vadalà, Pepe Valentina, Veronica Corazzari, Beniamino Palmieri. Genomic profiling in gynaecological oncology: the future is now![J]. European Journal of Gynaecological Oncology, 2020, 41(3): 323-325.
[11] A. Rossi, C.E. Garber, M. Ortiz, V. Shankar, D.Y. Kuo, N.S. Nevadunsky. Sustained effects of theory-based physical activity intervention for socioeconomically diverse obese endometrial cancer survivors: A Longitudinal analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 343-351.
[12] Guolin Liu, Rui Zhang. Postmenopausal recurrent retrovaginal extramural gastrointestinal stromal tumor: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 473-476.
[13] D. Korfias, J. Contis, M. Frangou-Plemenou, K. Gennatas, A. Kondis, D. Vlachodimitropoulos. Stem cells in ductal breast cancer: immunohistochemical expression of CD44, CD24, CD133, and ALDH-1 markers in 104 cases[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 36-41.
[14] A. Conversano, C. Balleyguier, M.K. De Fremicourt, H. Alkhashnam, C. Mazouni, J. Arfi-Rouche, N. Leymarie, F. Rimareix. Magnetic seed localisation for non-palpable lesions in patients undergoing breast conservative surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 48-53.
[15] S.Wang, W.J. Chen, Z.M. Song, Q. Li, X. Shen, Y.D. Wu, L. Zhu, Q.X. Ma, D.M. Xing. Long non-coding RNA ROR accelerates the progression of breast cancer via promoting stemness in MCF-10A cells[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 106-109.
No Suggested Reading articles found!